$2.75
-0.33 (-10.71%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CVRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 5 observational · 3 with posted results
Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, Point72 Asset Management, L.P., +2 more) · FINRA short interest 7.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart FailureNCT07232030Primary Effectiveness EndpointRandomized · Open-label · Treatment | Not applicable | Recruiting | Device: Barostim System · Other: Usual care medical management | Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III | 2,500 | Jan 2033 | ≤ 2,357 d | 2026-08-19 |
| Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant HypertensionNCT01471834To access long-term adverse events in participants implanted with the BAROSTIM NEO System.Open-label · Treatment | Not applicable | Active, not recruiting | Device: BAROSTIM NEO System · Drug: Medical Management | High Blood Pressure | 40 | May 2012actual | — | 2025-07-15 |
| Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)NCT04502316observationalThe primary objective of this post-market registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that were recently implanted with the Barostim System. | — | Terminatedsponsor's stated reason: Participant follow-up through 12 months post-Barostim Implant sufficient for data collection and analysis purposes. | Device: Barostim™ System | Heart Failure | 435 | 2026-05-14actual | — | 2026-07-30 |
| BAROSTIM NEO Hypertension Pivotal TrialNCT01679132To assess long-term adverse events in subjects implanted with the BAROSTIM NEO System.Open-label · Treatment | Not applicable | Suspendedsponsor's stated reason: Company resources only allows adequate oversight for one pivotal trial at a time | Device: BAROSTIM NEO System and Medical Management | Uncontrolled Hypertension | 10 | Mar 2026 | — | 2025-07-15 |
| Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical EvidenceNCT05860348observationalChange in Six Minute Hall Walk | — | Terminatedsponsor's stated reason: Lack of enrollment | Device: Barostim™ System | Heart Failure | 5 | 2024-09-04actual | — | 2025-04-08 |
| BATwire Implant KitNCT04600791Freedom from Serious Adverse Events (SAEs) related to the implantation of the lead using the BATwire Implant Kit through 30 days post implantOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: 1\. Slow enrollment and enough experience gained from the first in human phase of the study and would like to evaluate the findings. | Device: BATwire Implant Kit | Heart Failure | 93 | 2024-08-28actual | — | 2025-03-30 |
| BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection FractionNCT02876042observationalChanges in Office Cuff Systolic Blood Pressure | — | Unknown status | Device: BAROSTIM NEO™ System | Heart Failure | 70 | Jul 2024 | — | 2023-04-20 |
| BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection FractionNCT02880618observationalChange in New York Heart Association Functional Classification at 6 months Post-Implant | — | Unknown status | Device: Barostim Neo™ System | Heart Failure | 500 | Jul 2024 | — | 2023-04-20 |
| BAROSTIM THERAPY™ In Resistant HypertensionNCT02880631observationalBlood Pressure Changes | — | Unknown status | Device: BAROSTIM NEO™ System | Hypertension | 500 | Jul 2024 | — | 2023-04-20 |
| Baroreflex Activation Therapy for Heart FailureNCT02627196results2026-03-10Rate of Cardiovascular Mortality and Heart Failure MorbidityRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: BAROSTIM NEO® System · Drug: Medical Management | Heart Failure | 1,090 | Oct 2023actual | — | 2026-03-10 |
| Rheos® Pivotal TrialNCT00442286results2017-03-20Percent of Patients With a 10mmHg or Greater Reduction in Office Cuff Systolic Blood PressureRandomized · Quadruple-masked · Treatment | Not applicable | Completed | Device: Rheos® Baroreflex Hypertension System | Hypertension | 591 | Jan 2016actual | — | 2017-03-20 |
| BAROSTIM® Hope for Heart Failure StudyNCT01720160Heart failure metric improvements from baselineRandomized · Open-label · Treatment | Not applicable | Unknown status | Device: BAROSTIM NEO® System · Other: Standard of care medical managment therapy for heart failure | Heart Failure | 98 | May 2015actual | — | 2019-05-14 |
| BAROSTIM NEO System in the Treatment of Heart FailureNCT01471860To assess long-term adverse events in Canadian participants implanted with the BAROSTIM NEO SystemOpen-label · Treatment | Not applicable | Unknown status | Device: BAROSTIM NEO System · Drug: Medical Management | Heart Failure | 94 | Sep 2014actual | — | 2019-11-04 |
| Baroreflex Activation Therapy in Heart FailureNCT01484288results2021-08-26Changes in Sympathetic Nervous System Activity (MSNA Bursts/Min)Open-label · Treatment | Not applicable | Completed | Device: Barostim Neo System | Heart Failure | 12 | Jul 2013actual | — | 2021-08-26 |
| Rheos System for the Treatment of HFpEF Heart FailureNCT00957073To ascertain long-term adverse events for subjects implanted with the device.Randomized · Open-label · Treatment | Not applicable | Completed | Device: Rheos® system | Heart Failure | 19 | Oct 2012actual | — | 2021-04-08 |
| Rheos® Diastolic Heart Failure TrialNCT00718939Assess left ventricular mass index (LVMI).Randomized · Double-masked · Treatment | Not applicable | Completed | Device: Rheos Baroreflex Activation Therapy System | Diastolic Heart Failure | 6 | Jul 2012actual | — | 2016-10-21 |
| Device Based Therapy in Hypertension TrialNCT00710190Demonstrate the safety of Rheos(TM) Baroreflex Hypertension Therapy (TM) System by evaluating all adverse events and estimating the system and procedure related adverse event rate.Open-label · Treatment | Not applicable | Completed | Device: Rheos Baroreflex Hypertension Therapy System | Hypertension | 46 | Oct 2011actual | — | 2016-10-21 |
| Device Based Therapy in Hypertension Extension TrialNCT00710294Describe the safety of Rheos Baroreflex Hypertension Therapy System by evaluating all adverse events and estimating the system and procedure related adverse event rate until and including the 13-month follow-up.Non-randomized · Open-label · Treatment | Not applicable | Completed | Device: CVRx Rheos Baroreflex Hypertension Therapy System | Hypertension | 50 | Oct 2011actual | — | 2011-10-31 |
| Rheos Feasibility TrialNCT01077180Rheos Feasibility StudyNon-randomized · Open-label · Treatment | Phase 2 | Completed | Device: Implantation of the Rheos System · Other: Standard of care medical management | Hypertension | 16 | Dec 2007actual | — | 2019-07-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19